Regeneron Pharmaceuticals (Nasdaq:REGN) has announced that the FDA has granted Priority Review of the supplemental Biologics License Application (sBLA) for Eylea (aflibercept) Injection to treat retinopathy of prematurity (ROP) in preterm infants. First approved in 2011 to treat wet age-related macular degeneration, aflibercept is a blockbuster drug. Last year, it generated $9.2 billion for Regeneron…
High-dose aflibercept supports sustained vision improvement in DME and wet AMD
Increasing the dose of Regeneron‘s and Bayer‘s aflibercept (Eylea) to 8 mg led to sustained treatment intervals in patients with neovascular eye disease, according to the Phase 2/3 PHOTON and Phase 3 PULSAR clinical trials. In both studies, dosing patients at the 8 mg dose level every 12 or 16 weeks achieved noninferiority compared to 2 mg every 8…
50 of 2021’s best-selling pharmaceuticals
Drug sales in 2021 hit record heights, with a handful of pharmaceutical companies handsomely rewarded for creating COVID-19 vaccines and treatments. This roundup of best-selling pharmaceuticals in 2021 highlighted a banner year for the industry. Pfizer alone raked in $36.9 billion in sales from the Comirnaty vaccine it developed jointly with BioNTech. Demand for the…